Lovenox + Aspirin for Infertility

Recruiting in Palo Alto (17 mi)

Overseen byBruce Shapiro, MD, PhD

Age: 18 - 65

Sex: Female

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 4

Recruiting

Sponsor: Fertility Center of Las Vegas

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?This prospective randomized trial will compare outcomes in patients receiving aspirin in combination with a low-molecular weight heparin and those under this center's standard protocol receiving neither medication, in order to determine if these medications may improve success rates.

Eligibility Criteria

This trial is for women aged 18-42 who want to have a frozen embryo transfer, including those using donated embryos or eggs. It's open to patients with any history of IVF cycles. Women must not be currently pregnant, under 18, unable to consent in English, using a surrogate, or have certain medical conditions like bleeding disorders.

Inclusion Criteria

Prior history of successful, failed, and/or canceled IVF cycles are allowed

I am a woman aged 18-42 with frozen embryos or eggs, seeking embryo transfer.

I can use genetically tested embryos for implantation, but it's optional.

+1 more

Exclusion Criteria

Hypersensitivity to aspirin, heparin, or benzyl alcohol

Currently participating in any other research study

Subject already had an embryo transfer under this study

+8 more

Participant Groups

The study is testing if Lovenox (a low-molecular weight heparin) combined with Aspirin can improve the success rates of thawed blastocyst transfers compared to standard protocols without these medications. Participants will be randomly assigned to either receive both drugs or none before their embryo transfer.

2Treatment groups

Experimental Treatment

Active Control

Group I: Treatment ArmExperimental Treatment3 Interventions

Patients randomized to receive aspirin and Lovenox will begin taking one "low dose" 81mg aspirin and one 40mg injection of Lovenox daily, on the day of progesterone start.

Group II: Control ArmActive Control1 Intervention

This arm receives neither medication.